CNSX:BOLT

Bolt Biotherapeutics Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume71,500 shs

Average Volume18,200 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive BOLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Bolt Biotherapeutics

Bolt Metals Corp., an exploration company, focuses on the acquisition and development of cobalt projects for lithium-ion battery industry. Its principal asset is the Cyclops nickel-cobalt project that covers an area of 5,000 hectors with 9 prospects located in Indonesia. The company was formerly known as Pacific Rim Cobalt Corp. and changed its name to Bolt Metals Corp. in February 2020. Bolt Metals Corp. is headquartered in West Vancouver, Canada.

BOLT Enters Into a Collaboration Agreement With Bristol Myers
September 9, 2021 | nasdaq.com

Cancer treament developer Bolt Biotherapeutics just signed a deal with Bristol-Myers Squibb, its third big partnership this year
September 8, 2021 | bizjournals.com

BRIEF-Bolt Biotherapeutics Announces Clinical Collaboration With Bristol Myers Squibb To Study BDC-1001 In Combination With Opdivo For Treatment Of HER2-Expressing Solid Tumors
September 8, 2021 | msn.com

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences
September 2, 2021 | finance.yahoo.com

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
August 26, 2021 | finance.yahoo.com

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
August 12, 2021 | finance.yahoo.com

Bolt Biotherapeutics Rings the Nasdaq Stock Market Opening Bell
July 6, 2021 | nasdaq.com

FINAL DEADLINE NEXT WEEK: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Peloton Interactive, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 21, 2021 | finance.yahoo.com

Bolt Biotherapeutics Inc
June 19, 2021 | bloomberg.com

Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Peloton Interactive, Inc.
June 19, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: CNSX
Industry: Industrial Metals & Minerals
Sub-Industry: N/A
Sector: Basic Materials
Current Symbol: CNSX:BOLT
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: pacificrimcobalt.com
Phone: 604-922-8272
Employees: 65
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.99 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Bolt Biotherapeutics.

4.9 Community Rank

Outperform Votes
Bolt Biotherapeutics has received 114 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bolt Biotherapeutics has received 39 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bolt Biotherapeutics has received 74.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bolt Biotherapeutics and other stocks. Vote “Outperform” if you believe BOLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BOLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bolt Biotherapeutics does not currently pay a dividend.
Dividend Growth
Bolt Biotherapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Bolt Biotherapeutics (CNSX:BOLT) Frequently Asked Questions

What stocks does MarketBeat like better than Bolt Biotherapeutics?: Wall Street analysts have given Bolt Biotherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bolt Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Bolt Biotherapeutics' key executives?: Bolt Biotherapeutics' management team includes the following people:
Mr. Ranjeet Sundher, Pres, CEO & Director (Age 55, Pay $204.14k)
Mr. Steven Edward Vanry C.F.A., CFA, CIM, CFO, Sec. & Director
Mr. Alwi Nabil, Country Financial Controller
Who are some of Bolt Biotherapeutics' key competitors?: Some companies that are related to Bolt Biotherapeutics include 37 Capital (JJJ), 3D Resources (DDD), A-Cap Energy (ACB), Accent Resources (ACS), ActivEX (AIV), Adriatic Metals (ADMLF), African Gold (A1G), Agora (API), Agrimin (AMN), Aguia Resources (AGR), Alara Resources (AUQ), Alderan Resources (AL8), Alicanto Minerals (AQI), Alice Queen (AQX) and Alita Resources Limited (A40.AX) (A40).
View all of BOLT's competitors.
What other stocks do shareholders of Bolt Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).
What is Bolt Biotherapeutics' stock symbol?: Bolt Biotherapeutics trades on the CNSX under the ticker symbol "BOLT."
How many employees does Bolt Biotherapeutics have?: Bolt Biotherapeutics employs 65 workers across the globe.
What is Bolt Biotherapeutics' official website?: The official website for Bolt Biotherapeutics is pacificrimcobalt.com.
Where are Bolt Biotherapeutics' headquarters?: Bolt Biotherapeutics is headquartered at 640 Galveston Drive, Redwood City, California 94063.
How can I contact Bolt Biotherapeutics?: Bolt Biotherapeutics' mailing address is 640 Galveston Drive, Redwood City, California 94063. The company can be reached via phone at 604-922-8272.

This page was last updated on 10/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.